ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 040,53
0,60%
Dow Jones
38 604,96
-0,21%
DAX
18 693,96
1,14%
Brent Oil
79,105
-2,10%
Bitcoin
69 860,74
3,12%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Intercept Pharmaceuticals Inc (ICPT)

  7. Intercept Pharmaceuticals Inc (ICPT) Actualités

ICPT

Intercept Pharmaceuticals (ICPT)

Intercept Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ICPT
DateHeureSourceTitreSymboleSociété
09/05/202414h00GlobeNewswire Inc.Intercept Announces New PBC Data Analyses to be Presented at Digestive Disease Week® 2024 ConferenceNASDAQ:ICPTIntercept Pharmaceuticals Inc
29/02/202414h30GlobeNewswire Inc.Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBCNASDAQ:ICPTIntercept Pharmaceuticals Inc
20/11/202318h09Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:ICPTIntercept Pharmaceuticals Inc
15/11/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ICPTIntercept Pharmaceuticals Inc
13/11/202320h49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ICPTIntercept Pharmaceuticals Inc
13/11/202314h00GlobeNewswire Inc.Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 2023NASDAQ:ICPTIntercept Pharmaceuticals Inc
10/11/202314h00GlobeNewswire Inc.Intercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting® 2023NASDAQ:ICPTIntercept Pharmaceuticals Inc
08/11/202322h44Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ICPTIntercept Pharmaceuticals Inc
08/11/202322h28Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:ICPTIntercept Pharmaceuticals Inc
08/11/202322h21Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ICPTIntercept Pharmaceuticals Inc
08/11/202315h21Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:ICPTIntercept Pharmaceuticals Inc
08/11/202315h13GlobeNewswire Inc.Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.NASDAQ:ICPTIntercept Pharmaceuticals Inc
08/11/202313h50Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:ICPTIntercept Pharmaceuticals Inc
08/11/202312h04Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:ICPTIntercept Pharmaceuticals Inc
06/11/202323h15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ICPTIntercept Pharmaceuticals Inc
11/10/202322h34Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:ICPTIntercept Pharmaceuticals Inc
11/10/202322h16Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:ICPTIntercept Pharmaceuticals Inc
10/10/202317h10Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:ICPTIntercept Pharmaceuticals Inc
28/09/202323h17Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:ICPTIntercept Pharmaceuticals Inc
26/09/202314h00GlobeNewswire Inc.Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver DiseasesNASDAQ:ICPTIntercept Pharmaceuticals Inc
05/09/202314h30GlobeNewswire Inc.Intercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor ConferencesNASDAQ:ICPTIntercept Pharmaceuticals Inc
02/08/202313h00GlobeNewswire Inc.Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:ICPTIntercept Pharmaceuticals Inc
26/07/202314h00GlobeNewswire Inc.Intercept to Announce Second Quarter 2023 Financial Results on August 2, 2023NASDAQ:ICPTIntercept Pharmaceuticals Inc
10/07/202316h41Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ICPTIntercept Pharmaceuticals Inc
23/06/202312h36Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ICPTIntercept Pharmaceuticals Inc
23/06/202312h30GlobeNewswire Inc.Intercept Announces Restructuring to Strengthen Focus on Rare and Serious Liver Diseases and Significantly Reduce Operating ExpensesNASDAQ:ICPTIntercept Pharmaceuticals Inc
23/06/202308h45GlobeNewswire Inc.Intercept Presents New Data Showing Significant Impact of OCA-bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver DamageNASDAQ:ICPTIntercept Pharmaceuticals Inc
23/06/202300h36Dow Jones NewsIntercept Pharma Discontinues NASH-Related Investment, Will Focus on Liver DiseasesNASDAQ:ICPTIntercept Pharmaceuticals Inc
22/06/202323h45GlobeNewswire Inc.Intercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASHNASDAQ:ICPTIntercept Pharmaceuticals Inc
16/06/202322h02Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ICPTIntercept Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ICPT

Dernières Valeurs Consultées

GATE
ICONSUSDT
$ICONS Token
BIT
I07573
INTESA SANPAOLO
BIT
TKA
Thyssenkrupp
BIT
S29092
Societe Generale Effekten
USOTC
TBCRF
Timbercreek Financial (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés